Trial Profile
Post-treatment Normallized Urodynamic Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Correlations With Voiding Diary, King's Health Questionnaire, and Overactive Bladder Sympto
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 29 Jun 2012 New trial record